BioCryst Pharma (BCRX) Posts Narrower than Expected Q4 Loss
Tweet Send to a FriendGet Alerts BCRX Hot Sheet
Price: $1.71 -1.16%
EPS Growth %: +30.8%
Financial Fact:
Loss from operations: -5.32M
Today's EPS Names:
LBIX, ESEA, ISS, More
EPS Growth %: +30.8%
Financial Fact:
Loss from operations: -5.32M
Today's EPS Names:
LBIX, ESEA, ISS, More
Trade BCRX Now!
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported Q4 loss of $0.20, 1 cent better than the analyst estimate of ($0.21). Revenue for the quarter came in at $17.8 million versus the consensus estimate of $16.86 million.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Applied Materials, Inc. (AMAT) Tops Q2 EPS by 3c, Offers Guidance
- Autodesk, Inc. (ADSK) Misses Q1 EPS by 3c, Offers Guidance
- Notable Winners and Losers from Q1 Earnings Season: (YRCW) (TSLA) (AVEO) (CRMB)
Create E-mail Alert Related Categories
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
